Needham Reiterates Buy on Stoke Therapeutics, Maintains $22 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Joseph Stringer reiterates a Buy rating on Stoke Therapeutics (NASDAQ:STOK) and maintains a $22 price target.
June 28, 2024 | 10:12 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Joseph Stringer has reiterated a Buy rating on Stoke Therapeutics and maintained a $22 price target, indicating confidence in the company's future performance.
The reiteration of a Buy rating and the maintenance of a $22 price target by a reputable analyst suggests a positive outlook for Stoke Therapeutics. This could lead to increased investor confidence and potentially a short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100